Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

𝐍𝐌𝐑𝐀-𝟖𝟔𝟏, a novel muscarinic M4 positive allosteric modulator (PAM) discovered at the Warren Center for Neuroscience Drug Discovery (WCNDD), has entered Phase 1 clinical trials in collaboration with Neumora Therapeutics.

Read the Press release here →

Next
Next

Craig Lindsley featured on Quantum Potential Podcast: Rewiring the Brain and Rethinking Pain